Optima Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Optima Capital’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12	Closed	-$596	–	1152
2025 Q4	$596	Buy	+12	New	+$583	﹤0.01%	1098

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Optima Capital's SUPN Position: Q1 2026 in Review

Optima Capital sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 12 shares — an estimated $596 sold.

Optima Capital first reported a position in SUPN in Q4 2025 and held it in 1 quarter. The position peaked at $596 in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Optima Capital reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Optima Capital sold 12 Supernus Pharmaceuticals shares in Q1 2026, an estimated $596.
Optima Capital first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Optima Capital's Supernus Pharmaceuticals position peaked at $596 in Q4 2025.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Optima Capital's 13F filing for Q1 2026, filed 5 May 2026.